Caredx Financials
This page shows Caredx (CDNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Caredx has an operating margin of -8.1%, meaning the company retains $-8 of operating profit per $100 of revenue. This below-average margin results in a low score of 4/100, suggesting thin profitability after operating expenses. This is down from 12.2% the prior year.
Caredx's revenue grew 13.8% year-over-year to $379.8M, a solid pace of expansion. This earns a growth score of 56/100.
Caredx carries a low D/E ratio of 0.36, meaning only $0.36 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.
Caredx's current ratio of 2.86 indicates adequate short-term liquidity, earning a score of 55/100. The company can meet its near-term obligations, though with limited headroom.
Caredx generates a -7.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 13.9% the prior year.
Caredx passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Caredx generates $-1.97 in operating cash flow ($42.0M OCF vs -$21.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
Caredx generated $379.8M in revenue in fiscal year 2025. This represents an increase of 13.8% from the prior year.
Caredx's EBITDA was -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 128.7% from the prior year.
Caredx reported -$21.4M in net income in fiscal year 2025. This represents a decrease of 140.6% from the prior year.
Caredx earned $-0.40 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 143.0% from the prior year.
Cash & Balance Sheet
Caredx held $65.4M in cash against $0 in long-term debt as of fiscal year 2025.
Caredx had 51M shares outstanding in fiscal year 2025. This represents a decrease of 7.0% from the prior year.
Margins & Returns
Caredx's operating margin was -8.1% in fiscal year 2025, reflecting core business profitability. This is down 20.3 percentage points from the prior year.
Caredx's net profit margin was -5.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21.4 percentage points from the prior year.
Caredx's ROE was -7.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.9 percentage points from the prior year.
Capital Allocation
Caredx invested $71.4M in research and development in fiscal year 2025. This represents a decrease of 1.5% from the prior year.
Caredx spent $87.8M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 16713.8% from the prior year.
CDNA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108.4M+8.3% | $100.1M+15.4% | $86.7M+2.4% | $84.7M-2.2% | $86.6M+4.5% | $82.9M-10.2% | $92.3M+28.1% | $72.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $19.3M+15.1% | $16.8M-0.4% | $16.8M-9.1% | $18.5M+11.5% | $16.6M-5.0% | $17.5M-11.2% | $19.7M+5.2% | $18.7M |
| SG&A Expenses | $28.7M+0.9% | $28.4M+2.7% | $27.7M+21.6% | $22.8M-29.6% | $32.3M+1.9% | $31.7M+2.7% | $30.9M+2.5% | $30.1M |
| Operating Income | -$6.0M-2355.3% | -$246K+97.8% | -$11.1M+16.8% | -$13.4M-115.8% | $84.4M+715.0% | -$13.7M-87.3% | -$7.3M+67.5% | -$22.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $345K+2400.0% | -$15K+87.2% | -$117K-301.7% | $58K-66.1% | $171K-14.5% | $200K+809.1% | $22K+126.5% | -$83K |
| Net Income | -$4.1M-345.3% | $1.7M+119.5% | -$8.6M+17.2% | -$10.4M-111.8% | $87.7M+924.5% | -$10.6M-130.1% | -$4.6M+76.8% | -$19.9M |
| EPS (Diluted) | N/A | $0.03+118.8% | $-0.16+15.8% | $-0.19 | N/A | $-0.20-122.2% | $-0.09+76.3% | $-0.38 |
CDNA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $413.2M-4.4% | $432.3M-2.7% | $444.3M-9.3% | $489.6M-0.3% | $491.1M+2.9% | $477.0M+2.2% | $466.8M+3.2% | $452.4M |
| Current Assets | $257.1M-14.4% | $300.3M-2.3% | $307.3M-12.3% | $350.2M-0.5% | $351.8M+5.3% | $334.1M+4.2% | $320.6M+5.8% | $303.1M |
| Cash & Equivalents | $65.4M-28.4% | $91.4M+34.0% | $68.2M-23.1% | $88.7M-22.6% | $114.7M+20.2% | $95.4M-0.4% | $95.8M+2.7% | $93.3M |
| Inventory | $26.7M-5.7% | $28.3M+1.5% | $27.9M+21.7% | $22.9M+17.6% | $19.5M+1.2% | $19.3M+0.2% | $19.2M-4.5% | $20.1M |
| Accounts Receivable | $42.6M-10.9% | $47.8M-29.0% | $67.4M-5.8% | $71.5M+10.6% | $64.6M-3.0% | $66.6M+0.7% | $66.2M+10.0% | $60.1M |
| Goodwill | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M |
| Total Liabilities | $110.1M-9.1% | $121.2M+3.7% | $116.9M+6.0% | $110.3M-2.1% | $112.6M-44.7% | $203.7M+0.8% | $202.1M+3.0% | $196.2M |
| Current Liabilities | $89.8M-9.3% | $99.0M+6.3% | $93.2M+9.3% | $85.3M-4.6% | $89.4M+9.7% | $81.4M+4.0% | $78.3M+11.6% | $70.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $0 | $0 | N/A |
| Total Equity | $303.1M-2.6% | $311.1M-5.0% | $327.4M-13.7% | $379.3M+0.2% | $378.4M+38.5% | $273.2M+3.2% | $264.7M+3.3% | $256.2M |
| Retained Earnings | -$735.4M-2.3% | -$719.0M-3.4% | -$695.2M-9.2% | -$636.6M-1.7% | -$626.2M+11.1% | -$704.3M-1.1% | -$696.8M-0.2% | -$695.5M |
CDNA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $21.4M-42.8% | $37.4M+277.5% | $9.9M+137.2% | -$26.6M-221.4% | $21.9M+74.8% | $12.5M-33.9% | $18.9M+223.8% | -$15.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$34.9M-382.7% | $12.3M-47.2% | $23.4M+1665.8% | $1.3M+162.8% | -$2.1M+85.3% | -$14.4M-23.9% | -$11.6M-142.0% | $27.7M |
| Financing Cash Flow | -$12.5M+52.9% | -$26.5M+50.8% | -$53.8M-8268.7% | -$643K+28.8% | -$903K-163.5% | $1.4M+129.3% | -$4.8M-280.4% | -$1.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $12.2M-52.3% | $25.6M-48.9% | $50.0M | $0 | $0 | $0 | $0-100.0% | $522K |
CDNA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -5.6%-5.3pp | -0.3%+12.6pp | -12.8%+3.0pp | -15.8%-113.3pp | 97.5%+114.0pp | -16.6%-8.6pp | -7.9%+23.4pp | -31.3% |
| Net Margin | -3.8%-5.5pp | 1.7%+11.5pp | -9.9%+2.4pp | -12.2%-113.5pp | 101.3%+114.1pp | -12.8%-7.8pp | -5.0%+22.6pp | -27.6% |
| Return on Equity | -1.4%-1.9pp | 0.5%+3.2pp | -2.6%+0.1pp | -2.7%-25.9pp | 23.2%+27.1pp | -3.9%-2.1pp | -1.8%+6.0pp | -7.8% |
| Return on Assets | -1.0%-1.4pp | 0.4%+2.3pp | -1.9%+0.2pp | -2.1%-20.0pp | 17.9%+20.1pp | -2.2%-1.2pp | -1.0%+3.4pp | -4.4% |
| Current Ratio | 2.86-0.2 | 3.03-0.3 | 3.30-0.8 | 4.11+0.2 | 3.94-0.2 | 4.100.0 | 4.09-0.2 | 4.32 |
| Debt-to-Equity | 0.36-0.0 | 0.39+0.0 | 0.36+0.1 | 0.290.0 | 0.30+0.3 | 0.000.0 | 0.00-0.8 | 0.77 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Caredx's annual revenue?
Caredx (CDNA) reported $379.8M in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Caredx's revenue growing?
Caredx (CDNA) revenue grew by 13.8% year-over-year, from $333.8M to $379.8M in fiscal year 2025.
Is Caredx profitable?
No, Caredx (CDNA) reported a net income of -$21.4M in fiscal year 2025, with a net profit margin of -5.6%.
What is Caredx's EBITDA?
Caredx (CDNA) had EBITDA of -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Caredx's operating margin?
Caredx (CDNA) had an operating margin of -8.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Caredx's net profit margin?
Caredx (CDNA) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Caredx's return on equity (ROE)?
Caredx (CDNA) has a return on equity of -7.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Caredx's operating cash flow?
Caredx (CDNA) generated $42.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Caredx's total assets?
Caredx (CDNA) had $413.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Caredx spend on research and development?
Caredx (CDNA) invested $71.4M in research and development during fiscal year 2025.
What is Caredx's current ratio?
Caredx (CDNA) had a current ratio of 2.86 as of fiscal year 2025, which is generally considered healthy.
What is Caredx's debt-to-equity ratio?
Caredx (CDNA) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Caredx's return on assets (ROA)?
Caredx (CDNA) had a return on assets of -5.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Caredx's Piotroski F-Score?
Caredx (CDNA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Caredx's earnings high quality?
Caredx (CDNA) has an earnings quality ratio of -1.97x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Caredx?
Caredx (CDNA) scores 42 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.